BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

ULTRAGENYX PHARMACEUTICAL — Lobbying — Receipts Report

LD-2 disclosure · 3rd Quarter - Report

ULTRAGENYX PHARMACEUTICAL

via AVIVA STRATEGIES (FKA MGB CONSULTING)

3rd Quarter (July 1 - Sep 30) · 2025Posted Oct 15, 2025Filing document ↗LDA record ↗

Income$38Kfee reported

Client

Name: ULTRAGENYX PHARMACEUTICAL
Description: Biopharma company
Location: California · United States of America

Registrant

Firm: AVIVA STRATEGIES (FKA MGB CONSULTING)
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
- ultrarare disease - newborn screening - pediatric priority review voucher
Lobbyistsmr MAX GABRIEL BRONSTEIN
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.